However, the former mutation has been described among the non-V600 BRAF mutations as a variant with level B prognostic significance in metastatic colorectal cancer, and a plausible therapeutic significance for this variant in patients with advanced refractory solid tumors and lymphomas has also been reported [49,50,51]. The gene discussed is BRAF; the disease is lymphoma.